James R. Meyers

SVP Comm Ops North America, Gilead Sciences.

Companies

Vera Therapeutics, Inc.Board member Nov 26, 2025 to now¹
SANGAMO THERAPEUTICS, INCBoard member Nov 26, 2019 to now²
CytomX Therapeutics, Inc.Board member Dec 27, 2018 to now³
Arbutus BiopharmaBoard member Oct 22, 2018 to May 24, 2024⁴
Gilead SciencesSVP Comm Ops North America Jan 24, 2007 to Feb 23, 2018⁵

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

SANGAMO THERAPEUTICS, INC SGMOQ99,600 shares⁶$11.0K at $0.11Jun 12, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

Jun 12, 2025Granted 25,000 shares of SANGAMO THERAPEUTICS, INC⁶
Jun 4, 2024Granted 25,000 shares of SANGAMO THERAPEUTICS, INC⁷
Jun 1, 2023Granted 13,900 shares of SANGAMO THERAPEUTICS, INC⁸
Feb 25, 2022Granted 12,500 shares of SANGAMO THERAPEUTICS, INC⁹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARVera Therapeutics, Inc., Board member
2
SEC EDGARSANGAMO THERAPEUTICS, INC, Board member
3
SEC EDGARCytomX Therapeutics, Inc., Board member
4
SEC EDGARArbutus Biopharma, Board member
5
SEC EDGARGilead Sciences, SVP Comm Ops North America
6
SEC EDGARSANGAMO THERAPEUTICS, INC shares after the filing of Jun 12, 2025
7
SEC EDGARForm 4 filed Jun 6, 2024
8
SEC EDGARForm 4 filed Jun 5, 2023
9
SEC EDGARForm 4 filed Mar 1, 2022